Scientific Advisor, Treatment Research Institute (TRI)
• Third-Party Payer Track: Advances in Treating Chronic Pain and Addiction
Tuesday, March 29, 2016, 3:30 pm to 4:45 pm
Dr. David Gastfriend, MD, is Scientific Advisor at the Treatment Research Institute (TRI), the research and policy resource behind the Addiction Severity Index (ASI), the American Society of Addiction Medicine (ASAM) Criteria Level of Care Certification, the National Parity Monitoring Project, and the Consumers’ Guide to addiction treatment. An addiction psychiatrist, Dr. Gastfriend directed addiction research at Massachusetts General Hospital and was an investigator in the NIDA Cocaine Collaborative Study, the NIAAA COMBINE Study, and the NIDA Clinical Trials Network. As Vice President at Alkermes, Inc., he directed publications on Vivitrol in clinical research and health economics. Dr. Gastfriend’s ASAM Criteria research contributed to their endorsement by most U.S. states, the VA and DOD. His 150 scientific publications include The ASAM Criteria and Addiction Treatment Matching. He is Chief Architect of CONTINUUM – The ASAM Criteria Decision Engine™ and has consulted to the governments of Belgium, China, Iceland, Israel, Norway, Russia and the United States.